Iruxol Mono

Collagenase Clostridium Histolyticum, Protease, the active ingredient in Iruxol Mono, is a collagenase enzyme presented as a topical formulation for skin application. It facilitates enzymatic debridement of necrotic tissue and supports remodeling of cutaneous wounds in patients with chronic or acute skin injuries.

GNH USA supplies Iruxol Mono as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Iruxol Mono is a topical collagenase used in the management of wounds that require enzymatic debridement. - Chronic venous leg ulcers: promotes removal of necrotic tissue to enhance healing. - Diabetic foot ulcers: assists in debridement of devitalized tissue, facilitating wound closure. - Pressure injuries (stage II–III): facilitates enzymatic debridement of damaged skin and underlying tissue.

Topical application of Iruxol Mono may be associated with local skin reactions and, rarely, systemic effects.

Common Side Effects: - Redness at application site: mild erythema may appear. - Local pain or burning: transient discomfort during or after use. - Itching: occasional pruritus around treated area. - Swelling: mild edema may develop.

Serious or Rare Side Effects: - Allergic reaction: hives, swelling, or rash indicating hypersensitivity. - Severe skin necrosis: excessive tissue breakdown beyond intended debridement. - Systemic hypersensitivity: anaphylaxis or severe systemic allergic response.

Precautions should be observed to minimize adverse outcomes. - Assess wound suitability: confirm presence of necrotic tissue before application. - Avoid healthy skin: do not apply to intact epidermis. - Infected wounds: use only under physician supervision when infection is present. - Monitor for allergic response: discontinue if signs of hypersensitivity appear. - Known hypersensitivity: avoid in patients with documented allergy to collagenase or protease enzymes. - Store at room temperature: keep in original container, protect from moisture and light.

Potential drug interactions may affect safety or efficacy. Major Interactions (Avoid): - Concurrent topical proteolytic enzymes: may cause excessive tissue breakdown. - Systemic anticoagulants: increased risk of bleeding at the wound site. Moderate Interactions (Monitor Closely): - Topical antibiotics: may alter local microbiome and affect healing. - Corticosteroid creams: may reduce enzymatic activity and delay debridement. - Chemotherapeutic agents: may impair wound healing and increase sensitivity.